AIHTA - Publications - Search - Items where Subject is "WI 250 Oesophagus"
Number of items at this level: 15.

Erdos, J. and Stanak, M. (2016): Magnetic sphincter augmentation device (MSAD) in patients with gastroesophageal reflux disease (GERD). Decision Support Document 101.

Falkner, E. and Wild, C. (2008): Clinical application of Tissue Engineering: An overview of International and Austrian Areas of Research with a critical analysis of selected applications . LBI-HTA Projektbericht 013.

Grössmann, N. (2021): Nivolumab (Opdivo®) as monotherapy for the treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OESCC). Update February 2021. Oncology Fact Sheet Nr. 26.

Grössmann, N. and Wolf, S. and Wild, C. (2021): Endoscopic plication therapy in patients with gastroesophageal reflux disease (GERD). Decision Support Document 127.

Mad, P. (2007): [Photodynamic therapy in the palliative treatment of malignant oesophageal stenosis]. HTA-Newsletter 58: pp. 3-4.

Mad, P. and Wild, C. (2007): [Photodynamic therapy for the treatment of malignant stenosis in the alimentary tract. HTA in hospitals]. Decision Support Document 03.

Nachtnebel, A (2015): Ramucirumab in combination with paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction carcinoma. DSD: Horizon Scanning in Oncology 54.

Schmidt , L. and Lohr, P. and Prenner, A. and Poerio, E. and Ceresola, E. and Andretta, M. and Cavazzana, A. (2019): Robot-assisted surgery in thoracic and visceral indications. HTA-Projektbericht 108.

Stanak, M. and Hawlik, K. (2017): Electric stimulation therapy in patients with gastroesophageal reflux disease. Decision Support Document 104.

Wild, C. (2005): [Targeted therapies]. ITA-Newsletter September 2005: pp. 11-12.

Wild, C. (2004): [Photodynamic therapy/PDT]. HTA-Newsletter 27: p. 4.

Wild, C. (2002): [The EndoCinch suturing system]. HTA-Newsletter 06: pp. 3-4.

Wild, C. (2015): Biodegradable stents for the treatment of refractory or recurrent benign oesophageal stenoses. Decision Support Document 89.

Wolf, S. (2021): Adjuvant nivolumab (Opdivo®) as monotherapy for the treatment of patients with oesophageal (OC) or gastro-oesophageal junction cancer (GEJC). Oncology Fact Sheet Nr. 59.

Wolf, S. : Pembrolizumab (Keytruda®) in combination with platinum and fluoropyrimidine based chemotherapyfor the treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus. Oncology Fact Sheet Nr. 54.

This list was generated on Tue Jul 27 03:00:22 2021 CEST.